ADMA Biologics Inc. (NASDAQ:ADMA) finished Wednesday with an addition of $0.43 to close at $4.49, an upside of 10.59 percent. An average of 2,148,938 shares of common stock have been traded in the last five days. There was a gain of $0.32 in the past week, and it reached a new high 21 times over the past 12 months. The last 20 days have seen an average of 1,712,139 shares traded, while the 50-day average volume stands at 1,809,480.
ADMA stock has increased by 29.39% in the last month. The company shares reached their 1-month lowest point of $3.42 on 07/13/23. With the stock rallying to its 52-week high on 08/10/23, shares of the company touched a low of $1.99 and a high of $4.30 in 52 weeks. It has reached a new high 5 times so far this year and achieved 15.72% or $0.58 in price. In spite of this, the price is up 4.42% from the 52-week high.
Valuation Metrics
ADMA Biologics Inc. (ADMA) stock’s beta is 0.80. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.61, the price-to-book (PB) ratio at 6.80.
Financial Health
The quick ratio of ADMA Biologics Inc. for the three months ended June 29 was 2.70, and the current ratio was 7.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.99 and a total debt to equity ratio of 0.99 for the quarter ending June 29. ADMA Biologics Inc.’s EBITDA margin for the year ending June 29 is -21.07%, while its operating margin for the same period stands at -13.90%. Its gross profit as reported stood at $35.27 million compared to revenue of $154.08 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, ADMA Biologics Inc.’s return on assets was -14.80%.
Earnings Surprise
For the three-month period that ended June 29, ADMA Biologics Inc. had $144.3 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$6.79 million in the quarter, while revenues of -$12.23 million were shrunk -268.34%. The analyst consensus anticipated ADMA Biologics Inc.’s latest quarter earnings to come in at -$0.02 per share, but it turned out to be -$0.03, a -50.00% surprise. For the quarter, EBITDA amounted to $1.67 million. Shareholders own equity worth $222.27 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at ADMA Biologics Inc. (ADMA) price momentum. RSI 9-day as of the close on 09 August was 74.90%, suggesting the stock is Overbought, with historical volatility in this time frame at 54.81%.
As of today, ADMA’s price is $4.17 +7.77% or $0.32 from its 5-day moving average. ADMA is currently trading +27.84% higher than its 20-day SMA and +43.92% higher than its 100-day SMA. However, the stock’s current price level is +10.44% above the SMA50 and +66.48% above the SMA200.
The stochastic %K and %D were 84.36% and 86.41%, respectively, and the average true range (ATR) was 0.18. With the 14-day stochastic at 85.73% and the average true range at 0.17, the RSI (14) stands at 70.22%. The stock has reached 0.07 on the 9-day MACD Oscillator while the 14-day reading was at 0.18.
Analyst Ratings
The consensus rating for ADMA Biologics Inc. (ADMA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ADMA, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is ADMA’s price target for the next 12 months?
Analysts predict a range of price targets between $4.50 and $6.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for ADMA Biologics Inc. (ADMA) stock is $5.13.
